US Breast Cancer Drug Market to Show Further Growth, Projects Kuick Research in Its New Report Available at MarketPublishers.com
27 Sep 2016 • by Natalie Aster
LONDON – Cancer is a disease that hits population of each country, and its incidence growth on an annual basis as well as its associated morbidity and mortality. Healthcare costs associated with this disease are also on the rise.
Lung and breast cancer are the leading causes of mortality. In the USA, for instance, breast cancer represents the most common diagnosed form of cancer.
The number of women diagnosed with invasive breast cancer is expected to amount to 246,700 in 2016.
Monoclonal antibodies rule the US marketplace given their superior pharmacological effects as well as availability of a large number of products in the segment.
Herceptin has been dominating the US market for years, but it is expected to lose this position in the near term given the fact that its patent is to expire in 2019, thus clearing the way for biosimilars.
Some other popular drugs represent Afinitor, Perjeta, and more. Perjeta is set to see massive sales through 2021 given its ongoing clinical development,
Targeted therapies are forecast to continue advancing the treatment. Some novel agents are set to be introduced to the market in the near future.
New research report “US Breast Cancer Drug Market Outlook 2022” drawn up by Kuick Research offer an insightful discussion of the US market for breast cancer drugs. The study contains a deep insight into a prevalence rate of this disease.
It covers breast cancer tendencies and risk undercurrents in detail. The report proceeds with an in-depth market outline. The research study investigates dynamics of this marketplace, as well.
It concentrates on major products and sheds light on the competitive environment. The research report profiles major companies and discusses future prospects the US market has.
Please note that extra shipping charges are applied upon purchase of a Hard Copy of the publication.
Other Marketplaces Explored by the Publisher Include:
More new studies by Kuick Research are available at its page.